The amplification and overexpression of MYCN primarily found in 25% of neuroblastomas [16] and in other tumours including medulloblastoma, retinoblastoma, small cell lung cancer, glioblastoma and other embryonal tumours [17] suggest the implication of MYCN dosage in cancer development and aggressive expressivity. Here, MYCN is linked to embryonal neoplasm.